The second meeting of the Pharmex 2025 Policy Council was held at the National Food and Drug Control Laboratory, with strong participation from major pharmaceutical associations, senior officials from the Ministry of Health, the Ministry of Industry, Mine and Trade (IMT), and the Ministry of Petroleum.

Engineer Faramarz Ekhteraei, Chairman of the Pharmex Policy Council, opened the meeting by underlining the critical importance of unity within the pharmaceutical ecosystem. “Pharmex 2025 represents a new era of coordination and purpose. By bringing together all key associations and ministries, we are laying the groundwork for industrial progress, export readiness, and strategic self-reliance,” he stated.

Dr. Mehdi Pirsalehi, Head of the Iranian Food and Drug Administration (IFDA), emphasized the pivotal role of domestic API manufacturers during last year’s turbulent market conditions.

“Without the active role of local API producers, the pharmaceutical industry would have faced much deeper difficulties,” he noted.

Pharmex was described as the primary showcase of Iran’s pharmaceutical manufacturing capacity, especially in the field of raw materials.

“This exhibition must act as a platform for regional visibility and a driver of international joint ventures,” Dr. Pirsalehi added, citing the country’s $2 billion pharmaceutical export target under the 7th Development Plan.

Meysam Karimi, Pharmex Executive Director and former Secretary of the Pharmaceutical Raw Materials Syndicate, described the council meetings as a strategic leap:

“For the first time, nearly all major pharmaceutical associations are actively participating in shaping the vision of Pharmex. This collaboration is what gives Pharmex its unique power and position in the industry.”

The Pharmex Council continues its coordinated efforts to elevate the exhibition beyond a trade show positioning Pharmex 2025 as a hub for investment, policy alignment, and international pharmaceutical partnership